Vyome (NASDAQ:HIND – Get Free Report) and TransEnterix (OTCMKTS:TRXDW – Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Profitability
This table compares Vyome and TransEnterix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vyome | -69.71% | -216.95% | -69.42% |
| TransEnterix | -2,149.15% | -83.74% | -64.94% |
Risk & Volatility
Vyome has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, TransEnterix has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vyome | $303,085.00 | 58.43 | -$7.13 million | ($433.08) | -0.01 |
| TransEnterix | $8.53 million | 2.51 | -$154.20 million | ($4.22) | -0.04 |
Vyome has higher earnings, but lower revenue than TransEnterix. TransEnterix is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Vyome and TransEnterix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vyome | 0 | 0 | 2 | 0 | 3.00 |
| TransEnterix | 0 | 0 | 0 | 0 | 0.00 |
Vyome presently has a consensus target price of $15.00, suggesting a potential upside of 209.92%. Given Vyome’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Vyome is more favorable than TransEnterix.
Insider & Institutional Ownership
22.1% of Vyome shares are held by institutional investors. Comparatively, 8.2% of TransEnterix shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Comparatively, 3.1% of TransEnterix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Vyome beats TransEnterix on 9 of the 14 factors compared between the two stocks.
About Vyome
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
About TransEnterix
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
Receive News & Ratings for Vyome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyome and related companies with MarketBeat.com's FREE daily email newsletter.
